STTK biotech catalysts & pipeline

SHATTUCK LABS INC · Data as of 2026-10-25

Upcoming catalysts

SL-846 — Initial data

in 2027

We expect to share additional pre-clinical data, including data from our ongoing non-human primate toxicology study for SL-846, in the second half of 2026, and to share initial Phase 1 clinical data for SL-846 in 2027.

Source filing

SL-325 — Topline data

H1 2028

Primary endpoint is endoscopic response at 12 weeks. These data are expected in the first half of 2028.

Source filing

SL-846 — Conference presentation

H2 2026

We expect to share additional pre-clinical data, including data from our ongoing non-human primate toxicology study for SL-846, in the second half of 2026, and to share initial Phase 1 clinical data for SL-846 in 2027.

Source filing

Explore the free biotech catalyst calendar